Oncolytics Biotech Stock Price

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Oncolytics Biotech Inc ONCY NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
0.00 0.0% 1.99 0.00 0.00 0.00 1.99 20:00:00
Bid Price Ask Price Spread Spread % News
1.98 2.00 0.02 1.0% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.99 USD

Oncolytics Biotech Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 80.58M 40.49M 18.75M $ - $ - -0.78 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Oncolytics Biotech News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ONCY Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.992.151.952.04518,8890.000.0%
1 Month1.882.241.832.02625,1460.115.85%
3 Months2.112.921.832.28898,597-0.12-5.69%
6 Months2.712.920.922.09815,748-0.72-26.57%
1 Year1.046.020.3512.33927,8030.9591.35%
3 Years5.857.400.3512.37470,271-3.86-65.98%
5 Years5.857.400.3512.37470,271-3.86-65.98%

Oncolytics Biotech Description

Oncolytics Biotech Inc. is developing an intravenously delivered immuno-oncolytic virus called pelareorep, for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: 1) induces selective tumor lysis, and 2) promotes an inflamed tumor phenotype through innate and adaptive immune responses. Our clinical development plan is based on these two components of the mechanism of action, with a focus on obtaining regulatory approval as soon as possible.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.